Search

Amgen Inc

Închisă

SectorSănătate

390.3 3.07

Rezumat

Modificarea prețului

24h

Curent

Minim

375.75

Maxim

385.11

Indicatori cheie

By Trading Economics

Venit

486M

1.8B

Vânzări

-1.3B

8.6B

P/E

Medie Sector

26.184

64.641

EPS

5.15

Randament dividend

2.57

Marjă de profit

21.107

Angajați

31,500

EBITDA

-1.2B

3.9B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

-4.84% downside

Dividende

By Acuity

Randament dividend

Medie Sector

2.57%

2.31%

Următoarele câștiguri

4 aug. 2026

Data viitoare de dividende

11 sept. 2026

Următoarea dată ex-dividende

21 aug. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

20B

203B

Deschiderea anterioară

387.23

Închiderea anterioară

390.3

Sentimentul știrilor

By Acuity

28%

72%

87 / 340 Clasament în Healthcare

Amgen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 23:01 UTC

Amgen Inc. shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

31 iul. 2026, 20:07 UTC

News

Amgen's Board declared a quarterly dividend of $2.52 per share, while shares are trading lower amid rising Treasury yields and inflation concerns.

30 iul. 2026, 21:32 UTC

News

Amgen Inc announced a quarterly dividend of $2.52 per share, but shares are lower in after-market trading following mixed tech sector earnings.

29 iul. 2026, 23:26 UTC

Amgen Inc. shares traded roughly flat after-market, remaining above the 20-day moving average amid broader market volatility following the Federal Reserve's interest rate decision.

28 iul. 2026, 20:02 UTC

Social Media

Amgen Inc. shares are advancing, reaching an all-time high following the acquisition of Horizon, which enhances its focus on rare diseases and strategic growth areas.

27 iul. 2026, 23:22 UTC

Amgen Inc shares are higher in after-market hours, reaching a peak late in the session. Broader market sentiment remains positive amid reduced oil supply concerns.

24 iul. 2026, 23:31 UTC

Amgen Inc shares are higher in after-market trading, nearing the upper end of their one-month range. No specific news was identified to explain the movement.

23 iul. 2026, 23:26 UTC

News

Amgen Inc shares traded lower in after-market hours amid challenges in the biotechnology sector and increased credit risk perceptions in the investment-grade bond market.

22 iul. 2026, 23:11 UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and positioning above its 20-day moving average.

21 iul. 2026, 23:46 UTC

Amgen Inc shares are lower in after-market hours, reflecting a modest recovery from earlier losses. No specific news was identified to explain the movement.

20 iul. 2026, 19:56 UTC

Social Media

Amgen Inc. shares are lower today, reflecting broader market trends amid geopolitical tensions and inflation concerns. The stock ranks fourth in the SCHD ETF.

17 iul. 2026, 20:02 UTC

Macro Event

Amgen Inc. shares are lower during Friday's session, despite a rise in the Michigan Consumer Sentiment Index to 54.4 in July.

16 iul. 2026, 18:02 UTC

Amgen Inc. shares are higher today, diverging from broader market declines amid rising crude oil prices and geopolitical tensions. No specific news was identified.

15 iul. 2026, 19:16 UTC

Amgen Inc shares are higher Wednesday, reflecting a positive market trend amid investor interest in biotechnology despite geopolitical tensions affecting the bond market.

14 iul. 2026, 19:16 UTC

News
Macro Event

Amgen Inc. shares are lower amid pressure from recent product recalls due to quality control issues, impacting its reputation and operational efficiency.

13 iul. 2026, 19:46 UTC

News

Shares lower today despite price target increases from Guggenheim, UBS.

10 iul. 2026, 23:16 UTC

Amgen Inc. shares are higher in after-market trading, remaining near the upper end of their one-month range amid rising U.S. Treasury yields.

9 iul. 2026, 23:01 UTC

Amgen Inc shares are trading lower in after-market hours, following unusual trading activity with no specific news identified to explain the decline.

8 iul. 2026, 23:21 UTC

Amgen Inc shares are lower in after-market hours, reflecting broader market declines amid geopolitical tensions and a significant drop in the DAX 30 Index.

7 iul. 2026, 19:06 UTC

News

Truist Securities raised Amgen's price target to $340, maintaining a Hold rating. Shares are advancing, reflecting positive sentiment and long-term value creation.

6 iul. 2026, 20:06 UTC

News

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

2 iul. 2026, 23:06 UTC

News

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

1 iul. 2026, 19:11 UTC

Social Media

Amgen Inc shares are lower amid social media discussions on AI's impact on drug discovery and client platform risk perceptions in the biopharma sector.

29 iun. 2026, 19:11 UTC

News

Amgen Inc shares are higher today, supported by a broader market rally and investor confidence from South Korea's $576 billion investment plan in technology.

26 iun. 2026, 23:06 UTC

News

Amgen Inc shares declined in after-market trading following its revenue projections of $37.1 billion to $38.5 billion and significant debt of $57 billion.

25 iun. 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, continuing a recent positive trend with four consecutive sessions of gains. No specific news was identified.

24 iun. 2026, 23:01 UTC

Amgen Inc shares are lower in after-market hours, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

23 iun. 2026, 20:06 UTC

Amgen Inc shares are higher since Monday's close, reaching a session high earlier today. No specific company news was identified to explain the movement.

22 iun. 2026, 19:33 UTC

Biotechnology stocks support Amgen Inc's upward momentum today, with shares higher since Thursday's close despite pulling back from a session high.

18 iun. 2026, 22:06 UTC

Amgen Inc. shares are higher in after-market trading after notable volatility, contrasting with four consecutive lower closes. No specific news was identified for the move.

Comparație

Modificare preț

Amgen Inc Așteptări

Obiectiv de preț

By TipRanks

-4.84% jos

Prognoză pe 12 luni

Medie 360.52 USD  -4.84%

Maxim 427 USD

Minim 303 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAmgen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

7

Cumpărare

9

Păstrare

1

Vânzare

Sentiment

By Acuity

87 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat